Separately, on June 6, 2025, the committee approved RSU grants covering an aggregate of 98,348 shares of the Company's common stock to 25 new employees, with one-fourth of the shares vesting on May 16, 2026, and the balance vesting in equal quarterly installments over the following three years, also subject to continued employment with BridgeBio or its subsidiaries on each applicable vesting date. All of the above-described awards were made under the Plan. About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials.